Company News
- Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
May 11, 2021, 9:05 AM EDT - Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Apr 27, 2021, 9:05 AM EDT - Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
Apr 20, 2021, 9:25 AM EDT - Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
Mar 25, 2021, 8:35 AM EDT - Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 15, 2021, 8:05 AM EDT - Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
Mar 12, 2021, 8:05 AM EST - Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
Mar 10, 2021, 8:35 AM EST - Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
Mar 9, 2021, 9:05 AM EST - Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Mar 4, 2021, 9:10 AM EST - Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
Mar 1, 2021, 9:05 AM EST
